Research programme: antifungal therapeutics - Cyclenium Pharma
Latest Information Update: 13 Oct 2023
At a glance
- Originator Cyclenium Pharma
- Class Antifungals; Macrocyclic compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Mycoses
Most Recent Events
- 04 Jul 2023 Research programme: antifungal therapeutics - Cyclenium Pharma is available for licensing as of 04 Jul 2023. https://cyclenium.com/?page_id=622
- 04 Jul 2023 Early research in Mycoses in Canada (unspecified route) (Cyclenium Pharma pipeline, July 2023)